Filing Analysis
Unicycive Therapeutics entered into Amendment No. 2 to its existing At-The-Market (ATM) Sales Agreement with Guggenheim Securities on June 5, 2026. This amendment increases the total aggregate offering price of common stock available for sale through the ATM facility from $100 million to $150 million.
🚩 Red Flags
- Significant potential dilution: Increasing the ATM capacity by $50 million (a 50% increase over the previous limit) can lead to substantial dilution of existing shareholders, especially for a micro-cap company.
📋 Key Facts
- Amendment No. 2 to the Sales Agreement was executed on June 5, 2026.
- The total aggregate offering price for the ATM Offering increased from $100,000,000 to $150,000,000.
- The company filed a Shelf Registration Statement on Form S-3 on June 5, 2026, to facilitate the sale of an additional $50,000,000 in common stock.
- Guggenheim Securities, LLC continues to serve as the sales agent.
Unicycive Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing includes a press release providing a business update and financial performance details for the period.
📋 Key Facts
- Reported Q1 2026 financial results on May 12, 2026
- The financial period covered ended March 31, 2026
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- Included a press release as Exhibit 99.1
On April 6, 2026, Gaurav Aggarwal resigned from the Board of Directors of Unicycive Therapeutics, Inc. The company reported that the departure was not due to any disagreements regarding operations, policies, or practices.
📋 Key Facts
- Director Gaurav Aggarwal resigned effective April 6, 2026.
- The resignation was not the result of any disagreement with the Company, management, or the Board.
- The company is listed on the Nasdaq Capital Market under the symbol UNCY.
Unicycive Therapeutics, Inc. reported its full-year 2025 financial results and provided a business update on March 30, 2026. The filing is a routine disclosure of annual performance via a furnished press release.
📋 Key Facts
- Announced financial results for the full year ended December 31, 2025
- Press release issued and furnished on March 30, 2026
- Included a business update alongside the financial results
- The information is furnished under Item 2.02 and not considered 'filed' for liability purposes